A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo. (1st January 2018)

• Record Type: Journal Article
• Authors: Yoo, Youngbum; Yoon, Sun-Jung; Kim, So Yeon; Lee, Deok-Won; Um, Sewook; Hyun, Hoon; Hong, Sung Ok; Yang, Dae Hyeok
• Is Part Of: Drug delivery. Volume 25:Number 1(2018)
• Page Start: 1664
• Page End: 1671
• Publication Date: 2018-01-01
• Subjects: Glycol chitosan -- visible light irradiation -- doxorubicin⋅hydrochloride -- local drug delivery system -- thyroid cancer; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2018.1507058
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Systemic drug delivery systems (SDDSs) for thyroid cancer treatment are associated with serious side effects including nausea, anorexia, and hair loss as a result of damage to normal tissues. In this study, we investigated the feasibility of a local DDS (LDDS) based on visible light-cured glycol chitosan (GC) hydrogel and doxorubicin⋅hydrochloride (DOX⋅HCl), called GC10/DOX, on thyroid cancer treatment in vivo . Visible light irradiation increased the storage modulus and swelling ratio of the GC10/DOX hydrogel precursor. The release of DOX⋅HCl from GC10/DOX exhibited two unique patterns comprising an initial burst within 18 hours, followed by a controlled and sustained release thereafter. In vitro cell viability testing showed that GC10/DOX had a greater antitumor effect than free DOX⋅HCl and GC10 hydrogel controls. In vivo, local injection of GC10/DOX near tumor tissue led to a superior antitumor effect compared with controls consisting of free DOX⋅HCl intravenously injected to the tail vein of thyroid cancer-bearing mouse and GC10 hydrogel subcutaneously injected near the tumor. Altogether, our results suggest that GC10/DOX may have clinical potential for thyroid cancer treatment.